ReviewProteomics. Clinical applications2013
Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes.
Review in Proteomics. Clinical applications, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- Mass Spectrometry-Based Proteomics: Analyses Related to Drug-Resistance and Disease Biomarkers.Medicina (Kaunas, Lithuania) · 2023Review
- Conjugating immunoassays to mass spectrometry: Solutions to contemporary challenges in clinical diagnostics.Trends in analytical chemistry : TRAC · 2020Review
- Temporal Dynamics of High-Density Lipoprotein Proteome in Diet-Controlled Subjects with Type 2 Diabetes.Biomolecules · 2020Article
- Proteomic analysis of the cardiac extracellular matrix: clinical research applications.Expert review of proteomics · 2018Review
- Using LC-MS/MS-based targeted proteomics to monitor the pattern of ABC transporters expression in the development of drug resistance.Cancer management and research · 2018Article
- Unbiased and targeted mass spectrometry for the HDL proteome.Current opinion in lipidology · 2017Review
- Peptide serum markers in islet autoantibody-positive children.Diabetologia · 2017Article
- First-trimester multimarker prediction of gestational diabetes mellitus using targeted mass spectrometry.Diabetologia · 2016Article
- Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms.Proteomes · 2016Review
- The association of plasma cystatin C proteoforms with diabetic chronic kidney disease.Proteome science · 2016Article
- 4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer.Molecular oncology · 2016Article
- Adapting extracellular matrix proteomics for clinical studies on cardiac remodeling post-myocardial infarction.Clinical proteomics · 2016Review
- Selected Reaction Monitoring Mass Spectrometry for Absolute Protein Quantification.Journal of visualized experiments : JoVE · 2015Article
- Immunocapture-Selected Reaction Monitoring Screening Facilitates the Development of ELISA for the Measurement of Native TEX101 in Biological Fluids.Molecular & cellular proteomics : MCP · 2015Article
- High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk.BBA clinical · 2015Review
- Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics.Cholesterol · 2015Review
- Differentiation of type 2 diabetes mellitus with different complications by proteomic analysis of plasma low abundance proteins.Journal of diabetes and metabolic disorders · 2015Article
- Proteomic signatures of serum albumin-bound proteins from stroke patients with and without endovascular closure of PFO are significantly different and suggest a novel mechanism for cholesterol efflux.Clinical proteomics · 2015Article
- The Application of Multiple Reaction Monitoring to Assess Apo A-I Methionine Oxidations in Diabetes and Cardiovascular Disease.Translational proteomics · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Type 2 diabetes mellitus (T2DM) is an important risk factor for cardiovascular disease (CVD)--the leading cause of death in the United States. Yet not all subjects with T2DM are at equal risk for CVD complications; the challenge lies in identifying those at greatest risk. Therapies directed toward treating conventional risk factors have failed to significantly reduce this residual risk in T2DM patients. Thus newer targets and markers are needed for the development and testing of novel therapies. Herein we review two complementary MS-based approaches--mass spectrometric immunoassay (MSIA) and MS/MS as MRM--for the analysis of plasma proteins and PTMs of relevance to T2DM and CVD. Together, these complementary approaches allow for high-throughput monitoring of many PTMs and the absolute quantification of proteins near the low picomolar range. In this review article, we discuss the clinical relevance of the high density lipoprotein (HDL) proteome and Apolipoprotein A-I PTMs to T2DM and CVD as well as provide illustrative MSIA and MRM data on HDL proteins from T2DM patients to provide examples of how these MS approaches can be applied to gain new insight regarding cardiovascular risk factors. Also discussed are the reproducibility, interpretation, and limitations of each technique with an emphasis on their capacities to facilitate the translation of new biomarkers into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.